- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| LEPU BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| Di | LEPU BIO (02157): VOLUNTARY ANNOUNCEMENT INCREASE IN SHAREHOLDING BY THE CONTROLLING SHAREHOLDER | 1 | HKEx | ||
| Mo | LEPU BIO (02157): VOLUNTARY ANNOUNCEMENT CMG901 (AZD0901) CLINICAL RESULTS PRESENTED AS LBA PROFFERED PAPER AT PRESIDENTIAL SYMPOSIUM, MRG007 CLINICAL ... | 2 | HKEx | ||
| 23.09. | LEPU BIO (02157): VOLUNTARY ANNOUNCEMENT FOUR CLINICAL STUDIES SELECTED FOR PRESENTATION AT 2026 ESMO CONGRESS: CMG901 (AZD0901) CLINICAL TRIAL RESULTS ... | 1 | HKEx | ||
| 16.09. | LEPU BIO (02157): 2026 INTERIM REPORT | 2 | HKEx | ||
| 19.08. | Lepu Biopharma CO., LTD. H1 Sales Increase | 1 | RTTNews | ||
| 19.08. | LEPU BIO (02157): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | - | HKEx | ||
| 07.08. | LEPU BIO (02157): NOTICE OF BOARD MEETING | 1 | HKEx | ||
| 28.07. | LEPU BIO (02157): VOLUNTARY ANNOUNCEMENT POSITIVE TOP-LINE RESULTS ACHIEVED FROM CLARITY-GASTRIC01 GLOBAL PHASE III TRIAL OF CMG901 (AZD0901) | 3 | HKEx | ||
| 15.07. | LEPU BIO (02157): CHANGE OF EMPLOYEE REPRESENTATIVE SUPERVISOR | - | HKEx | ||
| 19.05. | LEPU BIO (02157): ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 19.05. | LEPU BIO (02157): (1) POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING HELD ON MAY 19, 2026; (2) APPOINTMENT OF SUPERVISOR; (3) CHANGE OF REGISTERED ADDRESS ... | - | HKEx | ||
| 06.05. | LEPU BIO-B (02157): DIS-APPLICATION OF RULES 18A.09 TO 18A.11 OF THE LISTING RULES AND REMOVAL OF STOCK MARKER | - | HKEx |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 288,62 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| DISC MEDICINE | 82,84 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update | Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026Launched Expanded... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,840 | 0,00 % | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,200 | 0,00 % | Summit Therapeutics: Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China | First Regimen to Achieve a Statistically Significant and Clinically Meaningful Overall Survival Benefit over an Anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,235 | -0,12 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| KINIKSA PHARMACEUTICALS | 97,48 | -0,08 % | Goldman Sachs raises Kiniksa stock price target on strong Arcalyst sales | ||
| KYMERA THERAPEUTICS | 122,55 | 0,00 % | Oppenheimer raises Kymera Therapeutics price target on drug data | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 12,585 | 0,00 % | MoonLake Immunotherapeutics AG: MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial | Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimabThe primary endpoint of ACR50 was met with a high response of 42.1% for sonelokimab's 60 mg with... ► Artikel lesen | |
| TANGO THERAPEUTICS | 22,510 | 0,00 % | Tango Therapeutics (TNGX) vs. CRSP and SMMT: Can Vopimetostat Turn Promising Cancer Data Into an 89% Upside? | ||
| RAPPORT THERAPEUTICS | 24,190 | 0,00 % | Rapport Therapeutics bricht ein: Großvolumige Kapitalerhöhung mit hohem Abschlag belastet Kurs | ||
| 4D MOLECULAR THERAPEUTICS | 12,780 | 0,00 % | 4D Molecular Therapeutics, Inc.: 4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME | 4D-150 is advancing into Phase 3 development for DME, a second multi-billion-dollar retinal disease market with significant unmet need First patients have been enrolled in 4SIGHT global Phase 3 trial... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 31,980 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Appoints Rob Scott, MD to Board of Directors | ||
| COGENT BIOSCIENCES | 31,980 | 0,00 % | Stifel bekräftigt Kaufempfehlung für Cogent Biosciences nach ESMO-Daten | ||
| PRIME MEDICINE | 5,225 | -0,29 % | Prime Medicine, Inc.: Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease | -- Global, first-in-human study underway designed to evaluate safety, tolerability, and initial clinical efficacy of PM577a -- -- PM577a is designed as a one-time therapy to correct the H1069Q mutation... ► Artikel lesen | |
| ABSCI | 12,100 | 0,00 % | Jefferies nimmt Absci mit "Buy" auf - Potenzial bei Wirkstoff gegen Haarausfall im Fokus |
Das Unternehmen LEPU BIOPHARMA CO LTD kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LEPU BIOPHARMA CO LTD finden Sie auf Wallstreet Online.